<DOC>
	<DOC>NCT00478569</DOC>
	<brief_summary>The primary objective is: 1) to describe adherence (and the main factors influencing adherence) to PTH(1-84) treatment when prescribed in a normal clinical setting. The secondary objectives are: 1. to describe the demographics and clinical characteristics of the patients that in a normal clinical setting are started on a treatment regimen with PTH(1-84) 2. to describe (using available data) the long term treatment effectiveness during the 24 months following initiation of PTH(1-84) treatment in a normal clinical setting 3. to monitor safety for 24 months following initiation of PTH(1-84) treatment in a patient in a normal clinical setting.</brief_summary>
	<brief_title>Adherence to PTH(1-84) Treatment (FP-002-IM)</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<criteria>According to the current Summary of Product Characteristics (SmPC) PTH(184) treatment initiated within one month preceding enrolment The patient's written informed consent to direct access and data processing must be obtained. According to the current SmPC The patient cannot participate in a clinical trial with PTH (all other trials allowed).</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>